New clinical program development fund awards $17.6 million in grants for Yale-New Haven Medical Center

May 09, 2001

New research at Yale in cancer, brain disorders, cardiovascular disease, developmental disorders and organ transplantation will be advanced with $17.6 million in grants from the New Clinical Program Development Fund (the Fund).

The Fund is a joint initiative created by the Yale-New Haven Health System, Yale-New Haven Hospital and Yale University School of Medicine to support the development and implementation of new clinical programs in the Medical Center (Yale University, Yale School of Medicine and Yale-New Haven Hospital working in cooperation).

According to Richard Edelson, M.D., deputy chair of the Fund and chair of dermatology at Yale, one of the goals of the initiative is to enhance the quality and scope of clinical services available at the Medical Center. The Fund will also be used to help achieve highly ranked national status in the five designated clinical priority areas.

"We want to position the Medical Center at the top of the field in as many target areas as possible," Edelson said. "Investment from the Fund is intended to allow these programs to push the envelope and in some cases to define the frontier."

Peter Herbert, M.D, chief of staff at Yale-New Haven Hospital and the Fund's co-chair, said the Fund invites proposals that present innovative approaches to diagnosing, treating and/or preventing diseases or disorders in the designated clinical areas. "We hope support from the Fund will result in the long term establishment of programs that have strong clinical applications with an appropriate research base," he said.

The clinical areas of funded proposals and physician applicants include:

Brain Disorders

* Clinical Neuroscience Center for Epilepsy and Neurovascular Diseases, Dennis Spencer, M.D.
* Yale-New Haven Medical Center Brain Tumor Center, Joseph Piepmeier, M.D.


* Transimmunization: A New Method for Treatment of Graft vs. Host Disease, Prevention of Graft Rejection and Immunization against Tumor Antigens, Michael Girardi, M.D.
* Expansion of the Yale Cancer Center Clinical Trials Office, Leonard Farber, M.D.
* New Infrastructure and Organization for the NCI Approved Yale Comprehensive Cancer Center, Vincent T. DeVita, Jr., M.D.
* Innovations of Head and Neck Management, Clarence Sasaki, M.D.

Cardiovascular Disease

* Yale New Haven Medical Center Endovascular Center, Bauer Sumpio, M.D.
* Integrated Program for the Treatment of End Stage Heart Disease, Barry Zaret, M.D.
* Endovascular Brachytherapy, Kenneth B. Roberts, M.D.

Developmental Disorders

* Yale New Haven Medical Center Oncofertility Center, Steven Palter, M.D.

Organ Replacement

* Transplantation, Marc Lorber, M.D.

The fund received 23 proposals in the first round with requests totaling $69.1 million and awarded $17.6 of the $18 million available. Two committees, co-chaired by Edelson and Herbert, and comprised of both School of Medicine and Hospital representatives, reviewed each proposal and made recommendations to Dean of Yale School of Medicine, David Kessler, M.D. and Yale-New Haven Hospital President and CEO, Joseph Zaccagnino, who made the final determinations.

The Fund is now calling for a second round of applications. In 2001, $11.5 million is available for funding support and the five clinical priority areas will remain the same. The application process begins with the submission of a two-page letter of intent that will be reviewed by the Fund's planning and development committees and the Strategic Development Committee of the Yale Medical Group. The Strategic Development Committee will help coordinate clinical initiatives between the Yale Medical Group and the Fund and ensure consistency with the school's clinical strategic plan.

Yale University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to